Datapoint: Ipsen’s Bylvay Scores New Liver Disease Nod

The FDA on June 13 approved Ipsen’s Bylvay (odevixibat) for the treatment of cholestatic pruritus due to Alagille syndrome, a rare genetic disorder that can cause liver damage, in patients 12 months of age and older. Ipsen bought the ileal bile acid transport inhibitor (IBATi) when it acquired Albireo Pharma, a biotech focused on rare diseases, for $925 million earlier this year. The once-daily therapy was first approved in 2021 for the treatment of cholestatic pruritus from progressive familial intrahepatic cholestasis, another pediatric liver disorder. It currently holds covered or better status for 75% of all insured lives under the pharmacy benefit, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 6/14/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 11

Datapoint: Kansas Rejects Medicaid Contract Challenges

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 10

Datapoint: FDA Approves Sandoz, Samsung Bioepis’ Stelara Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 9

Datapoint: FDA Approves Lilly’s New Alzheimer’s Drug

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today